As Sky News research revealed thousands of severely obese patients are facing severely delayed treatment, here we look at the ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

The updated standard replaces three previous guidelines and reflects the latest thinking on tackling obesity through the ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

People using weight loss medication have been told it's not a "quick fix" with many at risk of regaining their lost weight.

People using weight loss medication have been warned it is not a "quick fix" with many at risk of regaining their lost weight ...

Patients ending obesity medication or finishing a weight management programme should be offered support to help keep the ...